Wall Street brokerages forecast that AAC Holdings Inc (NYSE:AAC) will post earnings per share (EPS) of $0.11 for the current quarter, according to Zacks. Two analysts have provided estimates for AAC’s earnings. The lowest EPS estimate is $0.09 and the highest is $0.12. AAC posted earnings of $0.12 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.3%. The firm is expected to issue its next quarterly earnings results on Wednesday, May 2nd.
On average, analysts expect that AAC will report full-year earnings of $0.74 per share for the current year, with EPS estimates ranging from $0.70 to $0.77. For the next financial year, analysts expect that the business will post earnings of $0.96 per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for AAC.
AAC (NYSE:AAC) last posted its earnings results on Wednesday, February 21st. The company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.06. AAC had a negative net margin of 6.48% and a positive return on equity of 9.25%. The business had revenue of $86.10 million for the quarter, compared to analyst estimates of $72.82 million. During the same quarter in the prior year, the firm earned $0.15 EPS. The firm’s quarterly revenue was up 19.0% compared to the same quarter last year.
AAC (AAC) traded up $0.85 on Wednesday, hitting $10.95. 207,449 shares of the stock traded hands, compared to its average volume of 173,370. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 1.62. AAC has a fifty-two week low of $5.99 and a fifty-two week high of $13.06. The company has a market cap of $261.68, a price-to-earnings ratio of -15.00 and a beta of 1.62.
In related news, Director David C. Kloeppel sold 10,000 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $9.50, for a total transaction of $95,000.00. Following the transaction, the director now owns 202,580 shares in the company, valued at approximately $1,924,510. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director W Larry Cash purchased 5,000 shares of AAC stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average price of $9.92 per share, for a total transaction of $49,600.00. Following the transaction, the director now owns 30,000 shares in the company, valued at $297,600. The disclosure for this purchase can be found here. 33.99% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. acquired a new position in AAC during the 4th quarter worth about $114,000. California State Teachers Retirement System lifted its position in AAC by 1.5% during the 2nd quarter. California State Teachers Retirement System now owns 20,291 shares of the company’s stock worth $141,000 after buying an additional 300 shares in the last quarter. Alliancebernstein L.P. lifted its position in AAC by 3.8% during the 2nd quarter. Alliancebernstein L.P. now owns 20,600 shares of the company’s stock worth $143,000 after buying an additional 760 shares in the last quarter. GSA Capital Partners LLP acquired a new position in AAC during the 3rd quarter worth about $190,000. Finally, Nationwide Fund Advisors lifted its position in AAC by 116.4% during the 2nd quarter. Nationwide Fund Advisors now owns 34,414 shares of the company’s stock worth $238,000 after buying an additional 18,511 shares in the last quarter. Institutional investors and hedge funds own 64.27% of the company’s stock.
AAC Holdings, Inc is a provider of inpatient and outpatient substance abuse treatment services for individuals with drug and alcohol addiction. The Company performs drug testing and diagnostics laboratory services and provides physician services to its clients. As of June 30, 2016, the Company operated 12 residential substance abuse treatment facilities located throughout the United States, focused on delivering clinical care and treatment solutions across 1,139 beds, which includes 636 licensed detoxification beds, and 18 standalone outpatient centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AAC and related companies with MarketBeat.com's FREE daily email newsletter.